secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001549595-24-000120
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix to present updated Phase 1 NX-5948 data at investor meetings starting Sept 5
--------------------------------------------------------------------------------

- Company began investor roadshow on September 5, 2024, with an updated investor slide deck.
- Deck includes new data from the Phase 1 trial of NX-5948 for various B-cell malignancies.
- No specific numerical results (e.g., response rates, safety) are disclosed in this 8-K filing.
- NX-5948 is a targeted protein degrader; the full presentation may contain efficacy/safety details.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000120/0001549595-24-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000120/nrix-20240905.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer